Kymera Therapeutics Inc - ESG Rating & Company Profile powered by AI
Other companies in the rating peer group for Kymera Therapeutics Inc are displayed below. If you work at Kymera Therapeutics Inc and you wish to licence your ESG rating, please get in touch. Complete Sustainability analysis of Kymera Therapeutics Inc can be reached by registering for free.
Kymera Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.1; made up of an environmental score of 5.7, social score of 4.0 and governance score of 5.0.
5.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 958 | Provectus Biopharmaceuticals Inc | 5.2 | High |
| 958 | Vectura Group Services Ltd | 5.2 | High |
| 999 | Kymera Therapeutics Inc | 5.1 | High |
| 999 | Aequus Pharmaceuticals Inc | 5.1 | High |
| 999 | BioRestorative Therapies Inc | 5.1 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Kymera Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Kymera Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Kymera Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Kymera Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Kymera Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Kymera Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Kymera Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Kymera Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Kymera Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Kymera Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Kymera Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Kymera Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Kymera Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Kymera Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Kymera Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Kymera Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Kymera Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Kymera Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.